Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Trial of Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

NCT04769648 is registered in ClinicalTrials.gov with Glia, LLC as lead sponsor.

NCT NCT04769648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04769648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Trial of Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease
Lead sponsor
Glia, LLC
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 15, 2021
Completion date
October 15, 2023
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular graft-versus-host disease